PHARMACOLOGICAL EVALUATION OF ANTI-ULCER EFFECTS OF COMBINED DOSES OF ALOE VERA AND VITAMIN-E AGAINST INDOMETHACIN INDUCED PEPTIC ULCER MODELAbstract
Peptic Ulcer Disease (PUD) is one of the most prevalent pathogenic conditions which affects around 5-10% of the global population. Helicobacter pylori infection and the use of Non-Steroidal Anti-inflammatory Drugs (NSAIDs) are two of the most common etiological causes in the PUD pathogenesis. First line treatment for PUD involves use of drugs which cause acid suppression or target against the eradication of Helicobacter pylori infection. Ulceration generally occurs due to the disturbance of the normal equilibrium caused by either enhanced aggression or diminished mucosal resistance. Peptic ulcer disease (PUD) may also occur as a result of the regular usage of certain drugs, irregular food habits, stress, alcohol consumption, and so forth. Recent years have shown a significant increase in the consumption of NSAIDs, despite their harmful side effects. However, administration of NSAIDs, along with certain drugs or supplements may reduce the deleterious side effects. This research evaluates the ulcer protective efficacy of the combined dose of Aloe vera and vitamin-E in the Indomethacin-induced ulcerated rats. The therapeutic efficacy of the combined dose of drugs was compared with the disease control group and the standard drug Ranitidine. Data indicates that the administration of both individual and combined doses of Aloe vera and vitamin E showed a significant decrease (P˂0.001) in ulcer index, Ulcerated surface (%), gastric volume, total acidity and increase in the gastric pH. The efficacy of the combined dose of drugs was comparable with the control group and standard drug Ranitidine. This research presents the comparative study among the individual and combined doses of Aloe vera and vitamin E for their antiulcer efficacy in the Indomethacin administered healthy albino rats. It can help in further studies for their antiulcer efficacy in future work for new antiulcer drugs development.
A. Srivastava * and R. Singh
Hygia Institute of Pharmaceutical Education and Research, Faizullaganj, Lucknow, Uttar Pradesh, India.
12 January 2019
01 May 2019
13 June 2019
01 October 2019